GFH-009 is under clinical development by SELLAS Life Sciences Group and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL). According to GlobalData, Phase II drugs for Refractory Chronic Lymphocytic Leukemia (CLL) have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how GFH-009’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GFH-009 is under development for the treatment of refractory and relapsed acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), ewing sarcoma, rhabdomyosarcoma, neuroendocrine prostate cancer and lymphoma, peripheral t-cell lymphomas (PTCL), extranodal marginal zone b-cell lymphoma (mucosa-associated lymphoid tissue or MALT-lymphoma), diffuse large b-cell lymphoma, hodgkin lymphoma (b-cell hodgkin lymphoma). The drug candidate is administered by intravenous route. It acts by targeting cyclin-dependent kinase 9 (CDK9).
SELLAS Life Sciences Group overview
SELLAS Life Sciences Group (SELLAS) is a clinical biopharmaceutical company. Its products include GFH009, a highly selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor and galinpepimut-S. Galinpepimut-S (GPS), a cancer immunotherapeutic drug that targets Wilms tumour 1, is in Phase 3 clinical studies for the treatment of acute myeloid leukaemia and in Phase 1/2 clinical trials for the treatment of ovarian cancer. The company collaborates with Memorial Sloan Kettering Cancer Center (MSKCC), National Cancer Institute (NCI) and The University of Texas M.D. Anderson Cancer Center (MDACC) for conducting clinical trials targeting multiple cancer indications. SELLAS is headquartered in New York City, New York, the US.
For a complete picture of GFH-009’s drug-specific PTSR and LoA scores, buy the report here.